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Abstract
Alpha-synuclein (aSyn) plays a crucial role in Parkinson’s disease (PD) and other synucleinopathies, since it misfolds
and accumulates in typical proteinaceous inclusions. While the function of aSyn is thought to be related to vesicle
binding and trafficking, the precise molecular mechanisms linking aSyn with synucleinopathies are still obscure.
aSyn can spread in a prion-like manner between interconnected neurons, contributing to the propagation of the
pathology and to the progressive nature of synucleinopathies. Here, we investigated the interaction of aSyn with
membranes and trafficking machinery pathways using cellular models of PD that are amenable to detailed
molecular analyses. We found that different species of aSyn can enter cells and form high molecular weight species,
and that membrane binding properties are important for the internalization of aSyn. Once internalized, aSyn
accumulates in intracellular inclusions. Interestingly, we found that internalization is blocked in the presence of
dynamin inhibitors (blocked membrane scission), suggesting the involvement of the endocytic pathway in the
internalization of aSyn. By screening a pool of small Rab-GTPase proteins (Rabs) which regulate membrane
trafficking, we found that internalized aSyn partially colocalized with Rab5A and Rab7. Initially, aSyn accumulated in
Rab4A-labelled vesicles and, at later stages, it reached the autophagy-lysosomal pathway (ALP) where it gets
degraded. In total, our study emphasizes the importance of membrane binding, not only as part of the normal
function but also as an important step in the internalization and subsequent accumulation of aSyn. Importantly, we
identified a fundamental role for Rab proteins in the modulation of aSyn processing, clearance and spreading,
suggesting that targeting Rab proteins may hold important therapeutic value in PD and other synucleinopathies.
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Introduction
The aggregation and accumulation of proteins in the brain
is a common feature among several neurodegenerative
disorders such as Parkinson’s disease (PD) and dementia
with Lewy bodies (DLB) [24]. These diseases are part of a
group known as synucleinopathies, characterized by the
accumulation of proteinaceous inclusions enriched in
alpha-synuclein (aSyn) [55, 56, 59, 60, 64], an abundant
protein in the brain that is found in presynaptic terminals
and also in other subcellular compartments. The precise
physiological function of aSyn remains elusive, but it is
thought to be involved in synaptic vesicle trafficking and
biology [47]. aSyn can be divided into three distinct re-
gions based on the amino acid composition: the
N-terminal region (residues 1–60) adopts amphipathic
α-helical structure when associated with membranes ([13,
15]; the central region (residues 61–95) is highly hydro-
phobic and essential for aggregation ([23]; and the
C-terminal region (residues 96–140) is enriched in acidic
residues and is involved in several protein-protein interac-
tions [26], conferring to the protein a chaperone-like func-
tion [31, 43, 54]. aSyn is an intrinsically disordered protein
(IDP), characterized by the lack of defined secondary
structure under physiological conditions. However, aSyn
adopts helical structure in the first 100 residues upon
interaction with membranes [21, 28, 51].
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The precise physiological form of aSyn is still a matter of
debate. Initially, the protein was thought to be monomeric,
existing in a balanced equilibrium between a cytosolic, free
state, and a state bound to the plasma membrane and vesi-
cles. Recently, multimeric forms of aSyn, mainly tetrameric,
have been isolated from various cell types [3, 9, 65], initiat-
ing a debate about its natural state.
Several mutations in the SNCA gene have been identi-
fied in familial forms of PD (A53T [45], A30P [32],
E46K [67], H50Q [2], G51D [35] and A53E [44]). In
addition, overexpression of wild-type aSyn (aSyn WT)
due to duplication [16] or triplication [49] of the SNCA
gene are also associated with autosomal dominant forms
of PD.
Intense efforts have focused on the study of the mo-
lecular mechanisms underlying aSyn misfolding and ag-
gregation. Recently, cell-to-cell spreading of aSyn has
become an attractive model to explain the progressive
nature of these diseases and the typical patterns of path-
ology deposition in neuroanatomically connected regions
of the diseased brain. Multiple studies demonstrated that
aSyn oligomers and pre-formed fibrils (PFFs) enter cul-
tured cells and accumulate in the cytoplasm [37, 38, 63].
However, it is still unclear how aSyn enters cells and
where aggregation starts. The hypothesis that aSyn mul-
timerizes upon interacting with lipid membranes [9]
raised the question of whether α-helical aSyn multimers
directly transition into β-strand-rich cytotoxic forms, or
whether it is the unstructured, monomeric form that
transitions to aggregates inside cells, during the process-
ing and compartmentalization in different organelles and
the interaction with effector proteins.
We have previously shown that small Ras-like GTPases
(Rabs) proteins, key mediators of the membrane traf-
ficking and vesicle recycling, can also modulate aSyn
oligomerization and aggregation [5, 17, 25]. Rabs act as
molecular “switches” that alternate between two conform-
ational states: the GTP-bound ‘on’ form, and the GDP-
bound ‘off ’ form [57]. Notably, mutations in RAB genes
(e.g. RAB7L1 and RAB39B) and in their regulators or ef-
fectors have been implicated in several neurological and
neurodevelopmental disorders, suggesting that impair-
ment in the function of these proteins might be linked to
familial forms of PD [36, 48, 66].
Here, we investigated the internalization of aSyn
and the role of Rab proteins in mediating this pro-
cess. We found that membrane interactions by aSyn
enable internalization and that Rab proteins mediate
the intracellular distribution of the protein. In total,
our study provides novel insight into the molecular
mechanisms associated with aSyn internalization and
aggregation, paving the way for future intervention




aSyn WT, aSyn A30P and aSyn A11P/V70P were ob-
tained by transforming E.coli BL21-DE3 competent cells
with plasmids encoding corresponding cDNA sequences
(pET21-aSyn, pET21-A30P, pET21-A11P/V70P).
Purification was performed as previously reported [26]
with minor modifications. Briefly, BL21-DE3 cells were
grown in LB medium in the presence of ampicillin
(100 μg/ml). Protein expression was induced with 1 mM
IPTG for 4 h at 37 °C. Afterwards, cultures were har-
vested and the cell pellet was resuspended in Lysis Buf-
fer (50 mM Tris HCL, 150 mM NaCl, 1 mM EDTA and
Inhibitor Protease cocktail) at pH 8.0. Cells were recov-
ered, sonicated on ice, boiled for 20 min at 95 °C, and
cell debris were discarded by centrifugation. Subsequent
precipitation first with streptomycin sulphate (10 mg/
ml) and later with ammonium sulphate (361 mg/ml) was
used to obtain aSyn-enriched precipitate.
Anion exchange high-performance liquid-chromatography
(AEC) was carried out on an Äkta-HPLC Purifier (GE
Healthcare). The pellet was resuspended then in 25 mM
Tris-HCl (pH 7.7), and loaded onto a Mono Q column or
bounded to a Hi-Trap column (GE Healthcare). The mono-
meric proteins were eluted at ∼300 mM NaCl with a linear
salt gradient of elution buffer from 0 mM to 1 M NaCl. The
pure proteins (judged by PAGE) were dialyzed overnight
against the appropriate buffer and further size exclusion
chromatography (SEC) purification step using a Superdex 75
column (GE Healthcare) was performed.
Protein concentration was estimated from the absorb-
ance at 274 nm using an extinction coefficient of
5600 M− 1 cm− 1. The protein stocks were frozen in sin-
gle aliquots at − 80 °C.
Fibril formation
Three aliquots of 300 μL of aSyn WT were prepared
from the protein stocks, and diluted in phosphate saline
buffer (PBS) to reach a final concentration of 60 μM.
Samples were incubated in an Eppendorf Thermomixer
Comfort (Eppendorf, USA) with 0.02% sodium azide at
600 rpm and 37 °C.
The transition of aSyn from initial soluble monomeric
form to aggregated state was determined by measuring
light scattering in a Jasco FP-8200 spectrofluorometer
(Jasco Inc., MD, USA) with an excitation wavelength of
330 nm and emission range from 320 to 340 nm at 25 °
C. Solutions without protein were used as negative con-
trols. All experiments were carried out in triplicates.
Cell line cultures and treatments with aSyn
Human neuroglioma H4 cells were maintained at 37 °C
and 5% CO2 environment, in Opti-MEM medium (PAN,
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Germany) supplemented with 10% fetal calf serum (Ther-
moFisher) and 1% penicillin-streptomycin (ThermoFisher).
Cells were seeded in different well-plate formats, one
day prior to transfection, at a density of 8.5 to 1*105
cells/ml. The day after, cells were treated with different
concentrations of aSyn monomers or aSyn fibrils for
24 h. At the end of the treatment, cells were extensively
washed with PBS and then briefly treated with trypsin in
order to remove the residual proteins still outside of the
cells or bound to the dish (for a maximum time of 30 s),
incubated again with medium (in order to stop the tryp-
sinization) and then washed one last time with PBS.
Transfections were performed with calcium phosphate
following the procedure from www.flemingtonlab.com.
Shortly, 3 h prior to transfection, fresh cell medium
was added to the cells. DNA was diluted in 1× HBS
buffer with 25 mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid, 140 mM NaCl, 5 mM KCl,
0.75 mM Na2HPO4 ·2H2O, 6 mM Dextrose, pH 7.1.
After mixing, 2.5 M CaCl2 was added dropwise and
vigorously mixed. Followed 20 min of incubation, the
mixture was added dropwise to the cells. In the next
morning cells were fed with fresh medium.
Immunoblot analysis
Cells were solubilised with RIPA buffer (50 mM Tris pH 8.0,
150 mM NaCl, 0.1% Sodium-Dodecyl-Sulphate (SDS), 1%
Nonidet P40, 0.5% Sodium-Deoxycholate, protease inhibi-
tors) and protein quantification was done using the Bradford
assay (BioRad). All samples were measured in triplicate.
Cell lysates were separated by SDS-PAGE under redu-
cing conditions in 12% separating gels with 7% stacking
gels. After electrophoresis, proteins were transferred
onto 0.45 μm nitrocellulose membranes for 20 min per
membrane at constant 25 mA in a semi-dry transfer
chamber Trans-Blot® Turbo™ Transfer Solution from
Bio-Rad (Bio-Rad Laboratories, Inc., Hercules, CA,
USA). Free binding sites were blocked with 10% (w/v)
skim milk dissolved in TBS-T (50 mM Tris (hydroxy-
methyl)-aminomethane (TRIS) supplemented with 0.05%
(v/v) Tween-20) for 1 h at Room Temperature (RT).
For detection, the primary antibodies were dissolved in
TBS and incubated over night at 4 °C. Detection of proteins
on immunoblots was performed to detect aSyn, (aSyn
C-20, 1:1000, Santa-Cruz Biotechnology) β-actin (Actin
beta, 1:10.000, Sigma Aldrich), tubulin (tubulin β-III,
1:10.000, Santa-Cruz Biotechnology), transferrin receptor
(Tfr Receptor, 1:1000, Invitrogen-Life Technologies) and
Rab GTPases fused to GFP (GFP Ab, 1:1000, Roche). After
washing with TBS-T, secondary HRP-conjugated antibodies
(GE Healthcare) were diluted 10,000-fold in TBS-T and in-
cubated with the membrane for 2 h at RT.
Membranes were visualized using Fusion Fx (Vilber
Lourmat, Marne-la-Vallée, France) with Immobilon
Western Chemiluminescent HRP Substrate (Merck
Millipore, Billerica, MA, USA).
Dot blot analysis
All HPLC samples were boiled for 10 min at 95 °C at
650 rpm and then spun down briefly at 10,000 g and 4 °
C. Samples were loaded fully onto a 96 well
custom-manufactured Dot Blot machine. A vacuum
pump was used to suck sample through a 0.2 μm pore
size Protean nitrocellulose membrane (Schleicher &
Schuell Bioscience GmbH, Dassel, Germany). The mem-
brane was subsequently blocked with 5% skim milk in
TBS (to prevent unspecific staining) for 1 h.
Membranes were incubated with primary antibody (aSyn
BD transduction, 1:2000; BD Biosciences) diluted in 1%
skim milk in TBS, or 5% bovine serum albumin (BSA) in
TBS, overnight at 4 °C. At the end of the incubation, mem-
branes were washed three times with TBS-T for 10 min.
Subsequently, membranes were incubated with
HRP-conjugated secondary antibody (GE Healthcare) di-
luted 1:10,000 in TBS. Afterwards, membranes were visu-
alized using Fusion Fx (Vilber Lourmat, Marne-la-Vallée,
France) with Immobilon Western Chemiluminescent HRP
Substrate (Merck Millipore, Billerica, MA, USA).
Triton X-100 fractionation assay
Cells were plated and treated as described above. At the
end of the treatment, cells were lysed in Lysis Buffer I
(25 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA and
cocktail of protease inhibitors) and centrifuged at
100.000 g for 30 min at 4 °C. Supernatants were col-
lected (soluble fraction) and the pellets (insoluble frac-
tion) were washed with cold PBS and transferred to new
tubes. Samples were centrifuged once again 14.000 rpm
for 10 min at 4 °C and the resulting pellet, correspond-
ing to the insoluble fraction, was subsequently resus-
pended in Lysis Buffer II (75 mM Tris, pH 6.8, 3% SDS,
15% Glycerin, 3.75 mM EDTA pH 7.4 and a cocktail of
protease inhibitors). Finally, samples were sonicated (10
pulse/second) and immunoblotting analysis were per-
formed as described above.
Membrane biotinylation assay
The day before the experiment, cells were plated in
100 mm Petri dishes at a density of 4*106 cells, and
grown until 60–70% confluence. Thereafter, cells were
treated with 1 μM of aSyn recombinant monomers or fi-
brils of different aSyn variants (aSyn WT, aSyn A30P or
aSyn A11P/V70P) for 24 h.
At the end of the treatment, cells were treated as pre-
viously described [20, 46]. Briefly, cells were rinsed 3
times in ice-cold PBS and further incubated in PBS con-
taining 1.5 mg/ml of EZ-Link Sulfo-NHS-SS-Biotin
(ThermoFisher) with gentle rocking, for 30 min, at 4 °C.
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The non-bound biotin was removed by incubating cells
with 100 mM solution of Glycine for 15 min at 4 °C.
To remove the excess of glycine, cells were briefly
washed with PBS and thereafter cell lysate was prepared
in PBS containing Protease Inhibitor α-complete (La
Roche, Basel, Switzerland), 0.1% SDS and 1% Triton
X-100. The lysates were sonicated for 30 s and centri-
fuged for 5 min at 17000 × g. The supernatant was fur-
ther incubated with 100 μL of NeutrAvidin Agarose
Resin (ThermoFisher) for 2 h, in a rotatory shaker with
gentle agitation, at 4 °C. After the incubation with the
resin, the supernatant (corresponding to the Cytoplasmic
cell lysate fraction) was collected, and a Bradford assay
was performed to evaluate the amount of total protein
concentration in each of the samples.
Biotinylated proteins were then washed 3 times with
PBS and then eluted with 2× Laemmli Buffer by boiling
the samples at 95 °C for 5 min.
Samples were then processed by western blotting.
Transferrin receptor was used as a positive control of
the biotinylated fraction, whereas tubulin was used as a
positive control for the cytoplasmic cell lysate fraction.
Immunocytochemistry (ICC)
For ICC analysis, cells were plated in multi-well plates
with different formats, previously coated with coverslips.
24 or 48 h after transfection, H4 cells were washed with
PBS and fixed with 4% paraformaldehyde (PFA) for
10 min at RT, followed by a permeabilisation step with
0.5% Triton X-100 (Sigma Aldrich, St. Louis, MO, USA)
for 10 min at RT.
After blocking in 10% normal goat serum (PAA, Cölbe,
Germany)/DPBS for 1 h, cells were incubated with primary
antibody. Primary antibodies used were: rabbit anti-aSyn
(Human aSyn (C-20): sc-7011-R, 1:1000, Santa Cruz
Biotechnology, Dallas, USA) or mouse anti-aSyn (Human
aSyn, 610,787, 1:2000, BD Transduction), for 3 h or over-
night and secondary antibody (Alexa Fluor 555 donkey
anti-mouse IgG and/or Alexa Fluor 555 goat anti rabbit
IgG, (Life Technologies- Invitrogen, Carlsbad, CA, USA)
for 2 h at RT. In some of the experiments cells were incu-
bated with Phalloidin (Phalloidin 488, A12379, Phalloidin
594, A12381, 1:50 in PBS, ThermoFisher Scientific,
Massachusetts, USA), in order to stain acting filaments.
Phalloidin was added to the samples after the secondary
antibody, for 1–2 h at RT. Finally, cells were stained with
Hoechst 33,258 (Life Technologies- Invitrogen, Carlsbad,
CA,USA) (1:5000 in DPBS) for 5 min, washed again and
then fixed with Mowiol (Sigma Aldrich, St. Louis, MO,
USA) for epifluorescence and confocal microscopy.
Microscopy and imaging
Images in Fig. 1 and in Fig. 5 were acquired using a
Leica Inverted Microscope DMI 6000 B (Leica, Wetzlar,
Germany), using a 40× objective (HCX Pl Fluotar) or a
63× objective (HCX Pl Fluotar).
Total internal reflection (TIRF) microscopy was con-
ducted on a Zeiss Axio Observer.Z1 microscope
equipped with 405, 488, 561 and 639 nm lasers and an
Evolve 512 EMCCD camera (Photometrics) and Zen
Blue software, using 63× EC Plan-NEOFLUAR and 100×
α Plan-APOCHROMAT objectives.
For the screening of Rab proteins, images were taken
using an Olympus IX81-ZDC microscope system, with a
40× objective (FN 26,5). Sixty four images were ran-
domly taken using the Olympus Scan^R Image Analysis
Software in three independent experiments. Analysis of
the aggregation patterns were performed qualitatively,
by the experimenters, and the percentage of cells with
inclusions was determined.
All the other images were acquired using a Airyscan
Confocal Zeiss LSM800 with 40× or 63× oil immersion
objectives.
For the colocalization analysis in Fig. 3, the Pearson’s
R value was calculated via the use of Coloc2 plugin from
ImageJ.
For the mean fluorescence intensity values in Figs. 8
was used Fiji (ImageJ) Software and GraphPad Prism for
the statistical analyses and graph generation.
NMR experiments
All NMR spectra were recorded on Bruker 600 MHz
Avance III spectrometer, equipped with a cryogenically
cooled triple resonance 1H(13C/15N) TCI probe. Experi-
ments were recorded at 15 °C using protein samples dis-
solved in Buffer B supplemented with 10% D2O. For the
1H-15N HSQC experiments we used 16 scans, 1024
complex points (sweep-width of 16 ppm in the 1H di-
mension) and 256 complex points (sweep-width of
26 ppm in the 15N dimension). Sequence-specific assign-
ments for the backbone of aSyn WT and aSyn A11P/
V70P were transferred from previously published studies
[39, 42]. Only unambiguously assigned, well resolved
peaks were included in the analysis. The I/I0 ratios ob-
tained for aSyn WT and aSyn A11P/V70P, in absence
and presence of SUVs were plotted as a function of the
protein sequence to obtain the intensity perturbation
profiles [33]. Mean weighted chemical shifts displace-
ments (MWΔCS) for 1H-15N were calculated as
[(Δδ1H)2 + (Δδ15N/10)2]1/2.
Acquisition and processing of NMR spectra were per-
formed using TOPSPIN 3.2 (Bruker Biospin). 2D spectra
analyses were performed with CCPN.
SUV preparation
SUVs were prepared from a molar ratio of 1:1 of Coagu-
lation Reagent I containing DOPE:DOPS:DOPC (5:3:2
w/w) and DOPC (both Avanti Polar Lipids Inc., USA)
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dissolved in chloroform yielding a final molar ratio of
DOPE:DOPS:DOPC (5:3:12 w/w). The lipid solution
formed a thin film under evaporation of the solvent
with nitrogen gas and was further dried by lyophi-
lization under vacuum. The dried phospholipids were
dissolved in MES buffer (20 mM MES, 100 mM
NaCl, pH 6.5) and underwent several cycles of
freeze-thawing and water bath sonication until the so-
lution became clear. The size distribution was also
checked by DLS. For the NMR experiments a SUV
stock solution of 85 mM (6.6% w/v) in respect to the
monomers was used.
Software and statistical analyses
Colocalization in ICC samples was measured by using
ImageJ software and Pierson’s Coefficient was calculated






Fig. 1 Recombinant aSyn monomers and fibrils are internalized by H4 cells. a Recombinant aSyn monomers (aSyn Mono) or fibrils (aSyn Fibrils)
were added to the cell culture medium and incubated for 24 h. b SDS-PAGE and immunoblot analysis of the recombinant monomeric or fibrillar
species of aSyn used in the experiments. The monomers show also the presence of a small fraction of dimers, as displayed by the faint band at
35 kDa. In the fibril preparation, one can observe the presence of higher molecular weight (HMW) species that are stable even on an SDS-PAGE. c
Western blot (WB) of H4 cells after treatment with aSyn, confirming the internalization of aSyn monomers or fibrils as seen by the increase in the
levels of aSyn in cells that were treated with monomers or fibrils (actin is used as a loading control). d Quantification of the immunoblots.
Statistical test was performed using one-way ANOVA followed by Tukey’s post-hoc tests, *p < 0.01. e Epifluorescence microscopy of cells treated
as indicated. Scale bar: 30 μm. f TIRF microscopy of cells treated with aSyn monomers or fibrils (green) and stained with Phalloidin (red) confirm
intracellular localization of aSyn. Scale bar: 30 μm
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the use of Coloc2 Plugin from Fiji (ImageJ software).
Figures were composed with CorelDRAW X8 (Corel
Corporation, Ottawa, Canada) or with Microsoft Power
Point (Microsoft Corporation).
Statistical analysis was performed using Microsoft
Excel (Microsoft Corporation) and GraphPad PRISM 5
(GraphPad Software, San Diego, CA, USA). Images were
processed with ImageJ V1.41, NIH, USA and/or Corel-
DRAW X8 (Corel Corporation, Ottawa, Canada).
Statistical tests performed were Student’s-two-tailed
t-test, one-way-Analysis of Variance (ANOVA) and
repeated-measures ANOVA for grouped analysis, followed
by Tukey’s post-hoc tests for multiple comparison.
Data were expressed as mean ± SEM and a 0.5% gen-
eral significance level was defined, with significance
levels as follows: *: p < 0.05; **: p < 0.01; ***: p < 0.001.
Results
aSyn is internalized and forms intracellular inclusions
In order to investigate the molecular determinants of
aSyn internalization, we compared the behaviour of two
distinct forms of recombinant aSyn (monomers or fibril-
lar aggregates, hereafter named fibrils) (Fig. 1a). aSyn
monomers and fibrils were generated as described in
Methods, and the species were characterized by Trans-
mission Electron Microscopy (TEM) [62] and by
SDS-PAGE (Fig. 1b). The preparation of aSyn monomers
showed also the presence of a smaller amount of dimers,
as illustrated by the band at ~ 35 kDa. Due to contrast-
ing studies reporting the ability of monomeric aSyn to
passively enter cells, we tested two different concentra-
tions of this form (1 μM and 5 μM), and 1 μM of fibrils
of aSyn (calculated based on the initial concentration of
monomeric aSyn). The internalization of aSyn was ana-
lysed by immunoblotting and by immunocytochemistry
(ICC) after 24 h of incubation with cells. Immunoblot
analysis revealed that both aSyn monomers and fibrils
were internalized, given the increase in the levels of aSyn
in treated cells (Fig. 1c and d). Furthermore, microscopy
analysis (confocal and TIRF microscopy) demonstrated
that, in cells exposed to monomeric aSyn, the protein
accumulated in distinct perinuclear puncta, whereas in
cells exposed to fibrils aSyn accumulated in larger cyto-
solic inclusions (Fig. 1e-f ).
aSyn interacts with the plasma membrane and
accumulates as high molecular weight species
Based on previously reported aSyn binding to membranes,
we hypothesized that the internalization of aSyn might in-
volve an interaction with the plasma membrane. In order
to test this, we performed a cell surface biotinylation assay
in cells treated with aSyn. aSyn was found in the biotinyl-
ated fraction treated with either monomers or fibrils, indi-
cating that extracellular aSyn interacted with the plasma
membrane (Fig. 2a and b), and then accumulated within
the cell in punctae (Fig. 1e-f).
To further investigate the biochemical nature of the
intracellular aSyn, we performed size exclusion chroma-
tography (SEC) of cell lysates, and then dot blot analysis
of the various fractions collected. Recombinant aSyn
monomers were assessed by SEC in parallel, in order
to establish the elution profile of this form of aSyn
(Additional file 1: Figure S1A and S1B).
As expected, dot blot analysis of non-treated cells (NT)
showed low signal, given the lower levels of aSyn (Fig. 2c).
In cells treated with aSyn monomers, we detected the pro-
tein in fractions C1 to C4 (black box, Fig. 2c) as reported
in the chromatogram (Additional file 1: Figure S1B). We
also detected aSyn in the final B fractions (from B6 to
B15, red box), indicating the presence of higher molecular
weight aSyn species as well (Fig. 2c). Such species were
also found in cells treated with aSyn fibrils (fractions B5 to
B11, red box), but not monomeric species of aSyn
(Fig. 2c), suggesting that the species accumulating in
the cells were biochemically distinct depending on the
species of aSyn added to the cells.
To further confirm the biochemical differences ob-
served, we performed differential fractionation of the cell
lysates using Triton X-100. Immunoblot analysis showed
higher levels of Triton X-100-soluble aSyn in cells
treated with monomers, and higher levels of Triton
X-100-insoluble aSyn in cells treated with fibrils, consist-
ent with the results of the SEC analysis (Fig. 2d, left
side). Interestingly, we also detected the formation of
high molecular weight aSyn species in cells treated with
monomeric aSyn, suggesting that, upon internalization,
aSyn monomers start to aggregate (Fig. 2d, right side).
Taken together, these results suggest that both mono-
meric and fibrillar aSyn enter cells and accumulate in
aggregated, high molecular weight species.
aSyn partially colocalizes with Rab5A and Rab7
Next, we performed a microscopy-based screen of mam-
malian Rab proteins in order to identify the interplay be-
tween aSyn and the trafficking pathways. The experiment
consisted of treating cells overexpressing each individual
mammalian Rab protein (fused to EGFP: Rab-GFP) with
aSyn monomers or fibrils in order to assess (i) the effect
of aSyn on the subcellular distribution of the Rab proteins,
and (ii) the effect of each Rab protein on the subcellular
distribution of aSyn. From the screen, we selected a set of
Rab proteins whose localization was altered, or that colo-
calized with aSyn (Additional file 2: Table S1). Of these,
we selected Rab4A, Rab5A and Rab7 since they resulted
in the strongest phenotype. Interestingly, the Rab proteins
identified in the screen are compatible with a hypothesis
that aSyn is internalized via an active endocytic mechan-
ism that then sorts the protein into vesicular
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compartments, such as endosomes and lysosomes
[57]. Therefore, we next focused our study on the
these Rab proteins.
First, we assessed the degree of colocalization of aSyn
and Rab5A-GFP, or Rab7-GFP, in cells treated with
aSyn monomers or fibrils (Fig. 3a). The colocalization
was quantified using the Coloc2 plugin of ImageJ
Software (Fig. 3b). In cells treated with aSyn mono-
mers, we observed a strong colocalization between
aSyn (in red) and Rab5A-GFP vesicles (in green) (Fig.
3a, left column, central panel), as well as a partial, al-
though weaker, colocalization with Rab7-GFP (Fig. 3a,
right column, central panel). Interestingly, the colocali-
zation was not observed when cells were treated with
Fig. 2 aSyn associates with membranes and forms high molecular weight species during the internalization process in H4 cells. a Immunoblot of the
biotinylation assay of cells treated with aSyn monomers or fibrils (tubulin is used as a loading control). b Quantification of the levels of aSyn present in
the biotinylated fraction (membrane-associated aSyn). Statistical test was performed using one-way ANOVA followed by Tukey’s post-hoc tests,
*p < 0.01 c Dot blot of the size exclusion chromatography fractions of lysates of untreated cells, cells treated with 1 μM of aSyn monomers, and cells
treated with 1 μM of aSyn fibrils. The black box highlights monomeric aSyn, while the red boxes highlight the presence of high molecular weight
species of aSyn. d Triton X-100 fractionation, with the soluble (left panel) and the insoluble fractions (right panel), treated as described
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aSyn fibrils. This supports the idea that the internaliza-
tion and sorting of aSyn monomers and fibrils is differ-
ent, as one might expect given their distinct
biochemical properties.
aSyn form inclusions in Rab4A-positive compartments
Next, we examined the interplay between Rab4A and aSyn.
We found no effect on the distribution of Rab4A-GFP in
cells treated with aSyn fibrils. Likewise, we also found no
colocalization between Rab4A-GFP and aSyn in those cells
(Fig. 4, right panel). In contrast, when Rab4A-GFP-
expressing cells were treated with aSyn monomers, we
observed a prominent increase in the size of endosomes,
as well as a massive internalization of aSyn that accumu-
lated in compartments surrounded by large, abnormal
rings of Rab4A (Fig. 4, central panel on the top and lower
panels). This change in the size of early endosomes
suggested that exposure to aSyn monomers altered the
A
B
Fig. 3 aSyn partially colocalizes with Rab5A-GFP and Rab7-GFP in H4 cells. a ICC of cells transfected with Rab5A-GFP (right side of the panel) or
with Rab7-GFP (left side) and then treated with 1 μM of aSyn monomers or fibrils. b Pearson correlation coefficient reveals colocalization of aSyn
and Rab5A, and of aSyn and Rab7 in cells treated with aSyn monomers, but not with fibrils. Scale bar: 30 μm
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normal biology of Rab4A and, therefore, the endosome-
related trafficking processes.
Membrane binding properties are essential for the
internalization of aSyn
Based on the stronger effects of aSyn monomers, we de-
cided to focus on the effects of monomeric aSyn. To in-
vestigate whether intrinsic aSyn properties affected the
internalization of the protein, we took advantage of dif-
ferent aSyn mutants that have different membrane bind-
ing abilities. Specifically, we used WT aSyn, the aSyn
A30P familial mutant, known to display weaker binding
to membranes [4, 12, 29, 30, 61], and the artificial mu-
tant (A11P/V70P) designed to severely impair mem-
brane binding [8, 10]. First, we performed membrane
biotinylation assays with the different mutants, and de-
tected a clear trend in the amount of protein present in
the biotinylated fractions that reflected the different
membrane binding properties of the aSyn mutants (aSyn
A30P and aSyn A11P/V70P) (Fig. 5a and b). In particu-
lar, we detected a consistent trend in the levels of aSyn
dimeric species in the biotinylated fraction, suggesting
that membrane binding is important for dimerization
and aggregation of aSyn.
Next, we tested the ability of the two aSyn mutants to
enter cells and accumulate in intracellular inclusions, via
immunocytochemistry (ICC) approach. We observed a
significant reduction in the accumulation of aSyn in in-
clusions in cells treated with A30P or A11P/V70P aSyn
mutants when compared with cells treated with WT
aSyn (Fig. 5c), consistent with a difference in the intern-
alization of the mutants. We further quantified the in-
ternalization of the different variants of aSyn using
immunoblot analysis. We confirmed a strong difference in
the internalization of the various mutants (Fig. 5d and e),
although the amount of aSyn present in the medium was
identical (Fig. 5d).
Taken together, these results suggest that membrane
binding is essential for the internalization and, therefore,
for the formation of intracellular aSyn inclusions.
aSyn A11P/V70P is unable to bind membranes
To test the contribution of different aSyn regions to-
wards aggregation and membrane binding, several artifi-
cial mutants, such as the aSyn A11P/V70P have been
designed [9, 11]. First, we validated the effect of the
A11P/V70P mutation on the biding of aSyn to small
unilamellar vesicles (SUVs) (5:3:12 mixture of DOPE:
DOPS:DOPC) using NMR spectroscopy (Additional file 3:
Figure S2). While WT aSyn interacted with DOPE:
DOPS:DOPC SUVS, as previously described [22, 34]
(Additional file 4: Figure S3A, panel on the left), the
aSyn A11P/V70P mutant displayed a drastic reduction
(more than 80%) of the signal broadening starting from
residue 11 (where the first Pro mutation is located)
until residue 140 (Additional file 4: Figure S3A, panel
on the right), confirming the impairment in membrane
binding.
Next, we tested the effect of aSyn A11P/V70P in the
cellular model, in comparison to WT aSyn, and also in
the presence or absence of Rab4A-GFP, as we had ob-
served increased internalization of aSyn in H4 cells.
Using immunoblot analysis and ICC, we found that the
internalization A11P/V70P aSyn was negligible when
compared to that of WT aSyn (Additional file 4: Figure
S3B-D). Importantly, we did not detect internalization
when we increased the concentration of A11P/V70P
aSyn or when we overexpressed Rab4A-GFP, conditions
which significantly increased the levels of intracellular
WT aSyn (Additional file 4: Figure S3B-D).
Fig. 4 aSyn accumulates in Rab 4A-positive vesicles. ICC on H4 cells transfected with Rab4A-GFP and treated with 1 μM of aSyn monomers or
fibrils. Inset: zoom and separated channels of Rab4A-GFP aSyn. Arrows point to the large inclusions aSyn (in red, panel on the right) matching
with the GFP-positive Rab4A vesicles (in green, panel on the left). Scale bar: 30 μm
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The endocytic pathway is involved in the internalization
of aSyn
In order to investigate whether mutants with different
membrane binding properties altered the internalization
and intracellular fate of internalized aSyn, we used cells
overexpressing Rab4A-GFP, Rab5A-GFP, or a constitu-
tively active (CA) mutant of Rab5A-GFP. As described
above, WT aSyn was readily internalized and accumulated
in Rab4A-GFP-positive vesicles. In contrast, the internal-
ization of the artificial A11P/V70P aSyn mutant was
strongly impaired. Curiously, the PD-associated mutant
A30P displayed an intermediate phenotype (Fig. 6a-c).
Interestingly, the levels of internalized aSyn (monomers
and dimers) were higher in cells expressing these Rab pro-
teins than in naïve cells (shown above in Fig. 5d-e), sug-
gesting that increased levels of Rab4A altered the
dynamics of internalization and dimerization of aSyn. The
same trend was observed in in cells overexpressing
Rab5A-GFP indicating, once again, that stimulation of the
early steps of endosome formation increased the internal-
ization of aSyn, as long as the membrane binding proper-
ties of the protein are preserved (Fig. 6d-f). In cells
overexpressing Rab5A, we also observed an increase in
the levels of aSyn dimeric species.
Fig. 5 Membrane binding is essential for the aSyn internalization and inclusion formation. a and b Immunoblot and quantification of the
comparison of WT aSyn and two mutants (A30P and A11P/V70P) with different membrane-binding properties using a biotinylation assay. Dotted
bars refer to the band corresponding to aSyn dimers (aSyn**), and clear bars refer to aSyn monomers (aSyn*). c ICC and d immunoblotting of
non-treated (NT) cells, or cells treated with WT, A30P, or A11P/V70P aSyn for 24 h. Scale bar: 30 μm. e Quantification of the immunoblot in panel
D. Dotted bars refer to the band corresponding to aSyn dimers (aSyn**), and clear bars refer to aSyn monomers (aSyn*). Statistical tests were
performed using one-way ANOVA with repeated-measures for grouped analysis, followed by Tukey’s post-hoc tests. Data were expressed as
mean ± SEM and a 0.5% general significance level was defined, with significance levels as follows: *: p < 0.05; **: p < 0.01; ***: p < 0.001. Statistical
significance is indicated with the symbol “#” for the monomers, “+” for the dimers, and “*” for the combination between monomers and dimers
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Finally, to confirm the functional involvement of
Rab5A on the internalization of aSyn, we used a mutant
in which the GTPase activity is deregulated, resulting in
permanent activation - constitutively active mutant -
Rab5ACA-GFP (Fig. 6g-i). In cells expressing this mu-
tant Rab5A, we found overall higher levels of aSyn in-
ternalization, further confirming the role of the
endocytic pathway in the internalization of aSyn.
Rab7 sorts aSyn for degradation and reduces its
intracellular accumulation
Next, we investigated the intracellular fate of internal-
ized aSyn along the endocytic pathway by using
Rab7-GFP as a marker. Cells expressing Rab7-GFP were
treated with WT, A30P, or A11P/V70P aSyn mutants,
and analysed by ICC and immunoblotting, as described
above. Surprisingly, we found that the internalization of
aSyn, and the formation of dimers, was significantly re-
duced in cells overexpressing Rab7, and that there were
no differences in internalization between WT aSyn or
the two mutants. (Fig. 7a-c).
We hypothesized that this effect could be due to the
sorting of aSyn for degradation in the lysosome, due to
increased stimulation of the lysosomal pathway by over-
expression of Rab7. To test this, we repeated the experi-
ment in cells expressing a dominant negative (DN)
Fig. 6 The A30P and A11P/V70P aSyn mutants are less internalized than WT aSyn. a ICC and b Immunoblotting of cells transfected with Rab4A–
GFP and treated as in experiments shown in Fig. 5. d and e ICC and Immunoblotting of cells transfected with Rab5A-GFP and treated as above. g
and h ICC and Immunoblotting of cells transfected with Rab5ACA-GFP (constitutively active) and treated as above. c, f and i Quantifications of
the immunoblots in panels b, e and h. Dotted bars refer to the band corresponding to aSyn dimers (aSyn**), and clear bars refer to aSyn
monomers (aSyn*). Statistical tests were performed using one-way ANOVA with repeated-measures for grouped analysis, followed by Tukey’s
post-hoc tests. Data are expressed as mean ± SEM and a 0.5% general significance level was defined, with significance levels as follows: *: p < 0.05;
**: p < 0.01; ***: p < 0.001. Statistical significance is indicated with the symbol “#” for the monomers, “+” for the dimers, and “*” for the
combination between monomers and dimers. Scale bar: 30 μm
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mutant of Rab7 (Rab7DN-GFP) that impairs its activity.
Interestingly, we found that the internalization and
dimerization of aSyn was restored to the initial levels,
suggesting that the Rab7DN mutant blocked the sorting
of aSyn to the lysosome (Fig. 7d-f ).
The internalization of aSyn is mediated by dynamin
Next, we investigated the mechanism involved in the in-
ternalization of aSyn by using two well established
chemical blockers of endocytosis: PitStop2 (PitStop) and
Dyngo 4A (Dyngo).
Pitstop is a selective inhibitor of clathrin-mediated
endocytosis (CME) [50, 53], while Dyngo blocks all
dynamin-dependent endocytic mechanisms [40].
Naïve cells or cells overexpressing Rab4A-GFP were
treated with each of the two compounds for 30 min
prior to the treatment with aSyn monomers, and were
then incubated together with aSyn for 24 h and proc-
essed for ICC or immunoblotting, as described above.
In naive cells, Dyngo efficiently blocked the internal-
ization of aSyn (Additional file 5: Figure S4A). Yet,
the opposite effect was observed using PitStop, which
increased the accumulation of intracellular aSyn
(Additional file 5: Figure S4B-D).
Similarly, in cells overexpressing Rab 4A, Dyngo pre-
vented the internalization and accumulation of aSyn in
Rab4A-surrounded vesicles. In contrast, PitStop failed to
produce a significant effect (Fig. 8a-b).
Internalized aSyn is degraded by lysosomes
To investigate the fate of internalized aSyn, we tested
whether blocking lysosomal and autophagic function
would affect the levels of internalized aSyn. We treated
cells expressing Rab7-GFP with bafilomycin A1 or chloro-
quine for 30 min, and then added monomeric aSyn.
Cells were then incubated for 24 h, and then processed
for ICC analysis. We confirmed that blocking lysosomal
acidification and consequently autophagy inhibited the
degradation of internalized aSyn and led to its accumula-
tion, possibly in late endosomes and lysosomes (Fig. 8c-d).
Identical results were obtained in naïve cells (Additional
file 5: Figure S4, A-D). Interestingly, treatment with
chloroquine resulted in stronger accumulation of aSyn
than that observed with Bafilomycin A1, consistent
with chloroquine being more potent inhibitor then
bafilomycin A1.
Taken together, our results suggest that aSyn is inter-
nalized via dynamin-mediated endocytosis and trafficked
Fig. 7 Rab7 reduces the formation of dimers in cells treated with WT aSyn monomers. a ICC and b Immunoblotting of H4 cells transfected with
Rab7-GFP and treated as described above. d and e The overexpression of the Rab7 dominant negative (DN) does not affect the degradation of
the internalized aSyn. c and f Quantifications of the immunoblots in panels B and E. Dotted bars refer to the band corresponding to aSyn dimers
(aSyn**), and clear bars refer to aSyn monomers (aSyn*). Statistical tests were performed using one-way ANOVA with repeated-measures for
grouped analysis, followed by Tukey’s post-hoc tests. Data were expressed as mean ± SEM and a 0.5% general significance level was defined, with
significance levels as follows: *: p < 0.05; **: p < 0.01; ***: p < 0.001. The significance is shown with the symbol “#” for the monomers, with the
symbol “+” for the dimers and with the symbol “*” for the sum between monomers and dimers. Scale bar: 30 μm
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via the endocytic pathway and then sorted and targeted
for degradation via the autophagy-lysosomal system.
Discussion
A key premise for the prion-like spreading hypothesis of
aSyn pathology in PD and other synucleinopathies is that
aSyn assemblies are taken up by a recipient cell, are sorted,
and then seed the aggregation of endogenous aSyn, thereby
propagating pathology [6, 7]. Nevertheless, the precise mo-
lecular mechanisms involved are still elusive. Most studies
have focused on the understanding of the mechanisms
through which aSyn can be released from cells. However,
present understanding of the uptake and fate of internalized
aSyn are even more limited. Here, we focused on the initial
steps of this complex process, and investigated how mem-
brane binding properties might affect the internalization and
processing of aSyn in the cell. Using a simple cell-based
paradigm, we established that both monomeric and fibrillar
aSyn proteins can interact with the plasma membrane and
be internalized, accumulating in high molecular weight
species.
We also investigated the role of aSyn membrane binding
on internalization by using mutants that are known to
affect the membrane binding properties of aSyn. The
PD-associated mutant A30P displays reduced membrane
interactions and reduced internalization, when compared
to WT aSyn. Structurally, the substitution of the alanine
by the proline disrupts the α-helical domains formed in
the N-terminal and central regions of aSyn, thereby affect-
ing the ability of the protein to interact and bind to mem-
branes. Consistently, we found that the artificial mutant
A11P/V70P, designed to disrupt membrane binding [9,
11], indeed disrupts the N-terminal region and compro-
mises membrane binding, thereby impairing internaliza-
tion of aSyn. Interestingly, it has been widely suggested
that the aSyn A30P mutant may cause PD by affecting at
least partially different cellular pathways that those af-
fected by WT aSyn. Our study is consistent with this idea,
and forms now the basis for in vivo investigations of the
prion-like spreading ability of this mutant, which has not
been documented, since the studies performed thus far fo-
cused on WTaSyn [57–60].
Importantly, our findings suggest that one cannot dismiss
that, even monomeric aSyn might be sufficient to initiate
the process of aggregation and therefore, the spreading of
aSyn pathology. Only two studies have reported the intern-
alization of aSyn monomers and the involvement of the
endocytic pathway, although the purpose and the readouts
used in those studies were different [1, 58]. Interestingly, a
comparable study reported consistent results regarding tau,
suggesting that extracellular monomeric tau is sufficient to
initiate the spreading of tau pathology [41]. However, one
caveat of our study is the concentration of aSyn used, which





Fig. 8 Blocking endocytosis and autophagy modulates the internalization and degradation of aSyn. a ICC of Rab4A-GFP expressed in H4 cells
treated with 1 μM aSyn monomers and with vehicle, PitStop 30 μM or with Dyngo 50 μM. Both PitStop and Dyngo are inhibitors of the
endocytic processes. b Quantification of the aSyn mean fluorescence intensity in the three conditions. c ICC of Rab7-GFP-expressing cells treated
with 1 μM aSyn monomers and with vehicle, Bafilomycin 100 nM (Baf 100 nM), or with Chloroquine 50 μM (Chlq 50 μM). Bafilomycin and
Chloroquine are inhibitors of lysosomal acidification and, therefore, autophagy-lysosome pathway (ALP). (D) Quantification of the aSyn mean
fluorescence intensity in the three conditions. Scale bar: 30 μm
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Nevertheless, our study establishes proof of concept that,
perhaps a local and even just temporary increase in the
concentration of aSyn, caused for example by dying cells in
the brain, might lead to the release of monomeric aSyn that
could be internalized by neighbouring cells, thereby initiat-
ing the spreading of pathology.
Using selective inhibitors of the endocytic pathways,
such as Dyngo and PitStop, we demonstrate that aSyn is
internalized in a dynamin-dependent process, but not
through CME. It is possible that when clathrin-mediated
mechanisms are blocked (PitStop-related effects), the
clathrin-independent processes (blocked by Dyngo) which
are presumably involved in the internalization of aSyn are
exacerbated. In this way, a larger amount of aSyn can be
internalized in naïve cells (Additional file 5: Figure S4).
Additional studies are required to further dissect the mo-
lecular mechanisms involved in aSyn endocytosis.
In an unbiased screen of Rab proteins, we found that,
once internalized, aSyn partially colocalizes with Rab5A
and Rab7, suggesting that the endosomal pathway is
involved in the sorting and processing of aSyn. Further-
more, we demonstrated that Rab4A modulates the internal-
ization of aSyn, and surrounds the internalized protein.
Both Rab4A and Rab5A are localized in the early endo-
somes, contributing to the recycling/transport of proteins
to the plasma membrane, respectively. Rab7 is localized in
the late endosomes, lysosomes and phagosomes, contribut-
ing to the fusion of late endosome with lysosome [27]. Re-
cent studies suggest that, even when different Rabs localize
in the same compartment, they can occupy distinct mem-
brane microdomains with different functions, called Rab
domains. These are dynamic structures but, interestingly,
do not mix significantly over time [52]. One of the possible
explanations for this segregation mechanism is that it could
be, at least in part, mediated by effector proteins and their
association with additional molecules in the organelle
membranes [52]. Consistently, a recent study showed that
Rab4A is essential for the recruitment of adaptor proteins
to the tubular subdomain of the early endosomal mem-
brane, orchestrating a signalling cascade that initiates the
Fig. 9 Model for the proposed mechanism of aSyn internalization and interaction with the membrane and trafficking machinery. After interacting
with the plasma membrane, aSyn monomers are internalized through the endocytic pathway. Rab4A plays an important role in the sorting of
aSyn and on the transport from/to the plasma membrane. aSyn is then found in the early endosome and, it is possible that during the progress
from early to late endosome, due to acidification of the environment, aSyn monomers start to aggregate and form high molecular weight species.
Afterwards, late endosomes fuse with lysosomes, where aSyn can be degraded. It is possible that, during any of those steps, aSyn is released to the
cytoplasm and to the extracellular milieu, leading to its potential accumulation and spreading of pathology
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formation of a sorting platform from which multiple classes
of vesicular carriers emerge [18]. Based on the perturbation
of the morphology of Rab4A vesicles due to the interaction
with aSyn, we hypothesize that this particular GTPase cas-
cade nucleated by Rab4A is actively involved into the in-
ternalization of aSyn. Future studies should focus on the
precise molecular link between Rab4A and aSyn, and with
other potential effector proteins.
Our data are also consistent with the idea that aSyn aggre-
gation may be favoured by the low pH - that is reported to
vary between 5.0 and 6.0 - in endosomes [14], as well as by
molecular crowding due to the presence of acidic endosomal
proteins. It is also possible that aSyn aggregation occurs due
to problems in the late endosome-lysosomal compartments,
which we found to be involved in the degradation of aSyn.
Thus, impaired autophagic degradation of aSyn could lead to
the accumulation of aggregation-competent species [19].
Our data enable us to propose a model for the internal-
ization of aSyn, based on the interaction with trafficking
machinery components (Fig. 9). After interacting with the
membrane, aSyn monomers are internalized through the
endocytic pathway, where Rab4A plays an important role
on the protein sorting and on the transport from/to the
plasma membrane. aSyn is thereafter sorted to the early
endosome (in colocalization with Rab5A). It is possible
that during the progress from early to late endosome
(where it colocalizes with Rab7), due to pH acidification,
aSyn monomers start to oligomerize, and to assemble in
high molecular weight species, that can then escape to the
cytoplasm, leading to its accumulation and facilitating the
spreading of aSyn pathology.
Conclusions
In total, our study emphasizes the importance of mem-
brane binding for the internalization of aSyn and highlights
the fundamental role of Rab proteins in the internalization,
sorting, and processing of aSyn, suggesting that targeting
specific Rab proteins and/or specific intracellular trafficking
components might prove to be valuable targets for modu-
lating the spreading of aSyn pathology and, consequently,
disease progression in PD and other synucleinopathies.
Additional files
Additional file 1: Figure S1. Characterization of recombinant aSyn
monomers. (A) Fractions collected upon protein separation on Superose
6 10/300 size exclusion column. (B) Chromatogram of recombinant aSyn
monomers showing the fractions in which monomeric aSyn was
recovered. (PDF 190 kb)
Additional file 2: Table S1. Results of the Rab protein screen. Rab-GTPase
family members selected in a screen where we assessed alterations in the
subcellular distribution of the Rab protein or the colocalization with aSyn in
cells treated with aSyn monomers or fibrils. In the column “morphology”, a
“11% more Rab-vesicles” statement means that in the 11% of the cells ana-
lysed, the localization of Rabs is more vesicular (suggesting an increase of 11%
in the active, GTP-bound Rab protein) compared to the localization pattern
shown in naïve cells. In contrast, the statement “15% more cytosolic Rab”
indicates that, in this case, 15% of the cells analysed showed an increase in
the cytosolic, diffuse localization of Rab protein when compared to the naive
cells (suggesting an increase of 15% in the inactive, GDP-bound Rab protein).
(PDF 396 kb)
Additional file 3: Figure S2. Membrane binding and internalization of
the A11P/V70P aSyn mutant. (A) Membrane binding properties of WT
(left) and of A11P/V70P aSyn (right) in the presence of artificial small
unilamellar vesicles membranes (SUVs) [1:100 protein:SUVs ratio]. (B)
Immunoblotting of Rab 4A-GFP-expressing cells treated with 1 μM or
5 μM of WT or A11P/V70P aSyn. (C) Quantification of the immunoblots.
Dotted bars refer to the band corresponding to aSyn dimers (aSyn**),
and clear bars refer to aSyn monomers (aSyn*). Statistical tests were
performed using one-way-analysis of variance (ANOVA) with repeated-
measures for grouped analysis, followed by Tukey’s post-hoc tests. Data
were expressed as mean ± SEM and a 0.5% general significance level was
defined, with significance levels as follows: *: p < 0.05; **: p < 0.01; ***: p <
0.001. Significance is shown with the symbol “#” for the monomers, with
the symbol “+” for the dimers and with the symbol “*” for the sum
between monomers and dimers. (D) ICC of H4 cells transfected with Rab
4A-GFP and treated with 1 μM or 5 μM of aSyn wild type and aSyn
A11P/V70P. Scale bar: 30 μm. (PDF 3696 kb)
Additional file 4: Figure S3. Dyngo blocks whereas PitStop enhances
the internalization of aSyn. (A) ICC of H4 cells treated with 1 μM aSyn
monomers and with vehicle, PitStop 30 μM or Dyngo 50 μM. Both PitStop
and Dyngo are inhibitors of the endocytic processes. (B) Quantification of
the aSyn mean fluorescence intensity in the three conditions. Scale bar:
30 μm. (C) Immunoblotting of H4 cells treated with different concentrations
of PitStop and Dyngo. (D) Quantification of the immunoblot. Dotted bars
refer to the band corresponding to aSyn dimers (aSyn**), and clear bars
refer to aSyn monomers (aSyn*). Statistical tests were performed using
one-way-analysis of variance (ANOVA), with repeated-measures for grouped
analysis, followed by Tukey’s post-hoc tests. Data were expressed as mean
± SEM and a 0.5% general significance level was defined, with significance
levels as follows: *: p < 0.05; **: p < 0.01; ***: p < 0.001. Significance is shown
with the symbol “#” for the monomers, with the symbol “+” for the dimers
and with the symbol “*” for the sum between monomers and dimers. Scale
bar: 30 μm (PDF 1051 kb)
Additional file 5: Figure S4. Blocking of autophagy inhibits the
degradation of aSyn. (A) ICC of H4 cells treated with 1 μM aSyn monomers
and with vehicle, Bafilomycin 100 nM (Baf 100 nM), or with Chloroquine
50 μM (Chlq 50 μM). Bafilomycin and chloroquine are inhibitors of the ALP.
(B) Quantification of the aSyn mean fluorescence intensity in the three
conditions. Scale bar: 30 μm. (C) Immunoblotting of H4 cells treated with
1 μM aSyn WT and incubated with Bafilomycin 100 nM or Chloroquine
50 μM. (D) quantification of the immunoblot in panel C. Dotted bars refer to
the band corresponding to aSyn dimers (aSyn**), and clear bars refer to
aSyn monomers (aSyn*). Statistical tests were performed using one-way-
analysis of variance (ANOVA), with repeated-measures for grouped analysis,
followed by Tukey’s post-hoc tests. Data is expressed as mean ± SEM and a
0.5% general significance level was defined, with significance levels as
follows: *: p < 0.05; **: p < 0.01; ***: p < 0.001. Significance is shown with the
symbol “#” for the monomers, with the symbol “+” for the dimers and with
the symbol “*” for the sum between monomers and dimers. Scale bar:
30 μm. (PDF 1301 kb)
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